NRC Form 374
(5-84)

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 17

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93 – 438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Kalispell Regional Hospital Radiology Department	In accordance with application dated August 8, 1985
2. 310 Sunnyview Lane Kalispell, Montana 59901	3. License number 25-15463-01 is amended in its entirety to read as follows:
	4. Expiration date July 31, 1988
	5. Docket or Reference No. 030-09152

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A.
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 2 curies of each byproduct material authorized in Subitem 6.B.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 25-15463-01

Docket or Reference number 030-09152

Amendment No. 17

C.	Xenon-133	C. Gas or gas in solution that is the subject of an active (i.e., not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA or an active (i.e., not withdrawn, terminated or on "clinical hold") "Notice of Claimed Investigational Exemption for a New Drug" (IND) that has been accepted by FDA	C. 100 millicuries
D.	Iodine-131	D. Any iodine that has been manufactured, labeled, packaged, and distributed in accordance with a specific license issued pursuant to Section 32.72 of 10 CFR 32 or a specific license issued to a manufacturer by an Agreement State pursuant to equivalent State Regulations.	D. 50 millicuries
E.	Iodine-125	E. Sealed sources	E. 200 millicuries

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
25-15463-01

Docket or Reference number
030-09152

Amendment No. 17

9. Authorized use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

C. Blood flow or pulmonary function studies.

D. Treatment of hyperthyroidism and cardiac dysfunction.

E. For use in interstitial treatment of cancer.

CONDITIONS

10. Licensed material shall be used only at Kalispell Regional Hospital, 310 Sunnyview Lane, Kalispell, Montana.

11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

C. Read Vaughan, M.D.	Groups I, II, and III Xenon-133 Iodine-131 as iodide for treatment of hyperthyroidism and cardiac dysfunction
Robert F. Muller, M.D.	Groups I, II, and III Xenon-133 Iodine-131 as iodide for treatment of hyperthyroidism and cardiac dysfunction

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
25-15463-01

Docket or Reference number
030-09152

Amendment No. 17

12. (continued)

Michael B. Wickersham, M.D.	Groups I, II, and III Xenon-133 Iodine-131 as iodide for treatment of hyperthyroidism and cardiac dysfunction Iodine-125 for use in interstitial implants
David J. Rickles, M.D.	Iodine-125 for use in interstitial implants

13. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.

14. For a period not to exceed 60 days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:

    A. Has the prior written permission of the hospital's administrator and its Radiation Safety Committee, and

    B. Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and

    C. Performs only those procedures for which he is specifically authorized by a Nuclear Regulatory Commission license.

    The licensee shall maintain for inspection by the Commission, copies of the written permission specified in Subitem A above and of the license(s) specified in Subitems B and C above. These records shall be maintained for 5 years from the time the licensee grants its permission under Subitem A above.

15. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:

    A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of 10 half-lives.

B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity cannot be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.

C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

16. Sealed sources containing licensed material shall not be opened.

17. A. (1) Each sealed source containing licensed material, other than hydrogen-3, with a half-life greater than 30 days and in any form other than gas shall be tested for leakage and/or contamination at intervals not to exceed 6 months. In the absence of a certificate from a transferor indicating that a test has been made within 6 months prior to the transfer, a sealed source received from another person shall not be put into use until tested.

(2) Notwithstanding the periodic leak test required by this condition, any licensed sealed source is exempt from such leak tests when the source contains 100 microcuries or less of beta and/or gamma emitting material or 10 microcuries or less of alpha emitting material.

(3) The periodic leak test required by this condition does not apply to sealed sources that are stored and not being used. The sources excepted from this test shall be tested for leakage prior to any use or transfer to another person unless they have been leak tested within 6 months prior to the date of use or transfer.

B. The test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. The test sample shall be taken from the sealed source or from the surfaces of the device in which the sealed source is permanently mounted or stored on which one might expect contamination to accumulate. Records of leak test results shall be kept in units of microcuries and maintained for inspection by the Commission.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
25-15463-01

Docket or Reference number
030-09152

Amendment No. 17

17. (continued)

C. If the test reveals the presence of 0.005 microcurie or more of removable contamination, the licensee shall immediately withdraw the sealed source from use and shall cause it to be decontaminated and repaired or to be disposed of in accordance with Commission regulations. A report shall be filed within 5 days of the test with the U. S. Nuclear Regulatory Commission, Region IV, 611 Ryan Plaza Dr., Suite 1000, Arlington, Texas 76011, describing the equipment involved, the test results, and the corrective action taken.

D. Tests for leakage and/or contamination shall be performed by the licensee or by other persons specifically authorized by the Commission or an Agreement State to perform such services.

18. The licensee shall conduct a physical inventory every 6 months to account for all sealed sources received and possessed under the license. The records of the inventories shall be maintained for 2 years from the date of the inventory for inspection by the Commission, and shall include the quantities and kinds of licensed material, location of sealed sources and the date of the inventory.

19. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in:

A. Application dated October 15, 1982

B. Letter with attachments dated February 3, 1983

C. Letter dated October 10, 1984

D. Letter with attachments dated August 8, 1985

The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Original Signed By
C. L. Cain

Date SEP 20 1985

By _____
Nuclear Materials Safety Section
Region IV
Arlington, Texas 76011

Official Record Copy

1/1
ML40

UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION IV
611 RYAN PLAZA DRIVE, SUITE 1000
ARLINGTON, TEXAS 76011

BETWEEN: William O. Miller, Chief
License Fee Management Branch
Office of Administration

R. J. Everett, Chief
Material Radiation Protection Section, TPB,
DV&TP, RIV

LICENSEE FEE TRANSMITTAL

A. REGION IV

1. APPLICATION ATTACHED

Applicant/Licensee: Kalispell Reg. Hosp.

Application Dated: August 8, 1985

Control No.: 46836

License No.: 25-15463-01 (030-09152)

2. FEE ATTACHED

Amount: $120

Check No.: 7104

3. COMMENTS

Signed Laura Hurley

Date August 15, 1985

02120

B. LICENSEE FEE MANAGEMENT BRANCH

7/88

1. Fee Category and Amount: 1C - $120

2. Correct Fee Paid. Application may be processed for:

Amendment ✓

Renewal _____

License _____

Signed Peter Jacques /DD

Date 8/28/85